• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III

    2/6/24 7:59:51 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care
    Get the next $ALPA alert in real time by email
    SC 13G 1 tm245341d1_sc13g.htm SC 13G

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Carmell Corporation

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    142922103

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 142922103   SCHEDULE 13G   Page 2 of 8 Pages

     

    1  

    NAME OF REPORTING PERSON

    Newlin Investment Company 1, LLC 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) ¨

    3   SEC USE ONLY
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Florida 

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      5  

    SOLE VOTING POWER

    0 

      6  

    SHARED VOTING POWER

    1,249,062 

      7  

    SOLE DISPOSITIVE POWER

    0 

      8  

    SHARED DISPOSITIVE POWER

    1,249,062 

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,249,062 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ¨ 

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 (1)

    5.4% 

    12  

    TYPE OF REPORTING PERSON

    OO 

         

     

    (1) This percentage is calculated based upon 23,081,642 shares reported as outstanding as of November 14, 2023, in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 15, 2023, by Carmell Corporation (“Issuer”).

     

     

     

     

    CUSIP No. 142922103       Page 3 of 8 Pages

     

    1  

    NAME OF REPORTING PERSON

    William R. Newlin  

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨ (b) ¨

    3   SEC USE ONLY
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America 

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      5  

    SOLE VOTING POWER

    0 

      6  

    SHARED VOTING POWER

    1,249,062 

      7  

    SOLE DISPOSITIVE POWER

    0 

      8  

    SHARED DISPOSITIVE POWER

    1,249,062 

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,249,062(1) 

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

    ¨ 

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 (2)

    5.4% 

    12  

    TYPE OF REPORTING PERSON

    IN 

      

    (1) This percentage is calculated based upon 23,081,642 shares reported as outstanding as of November 14, 2023, in the Quarterly Report on Form 10-Q filed with the SEC on November 15, 2023, by Issuer.

     

     

     

     

    CUSIP No. 142922103       Page 4 of 8 Pages

     

    ORIGINAL REPORT ON SCHEDULE 13G

    Item 1.

     

      (a) Name of Issuer: Carmell Corporation
      (b) Address of Issuer’s Principal Executive Offices: 2403 Sidney Street, Suite 300, Pittsburgh, Pennsylvania 15203

     

    Item 2.

     

    (a) Name of Person Filing:

     

    Newlin Investment Company 1, LLC (“NLLC)

     

    William R. Newlin (“Mr. Newlin”)

     

    NLLC and Mr. Newlin are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    (b) Address of Principal Business Office or if None, Residence:

     

    The address of each of the Reporting Persons is 428 Beaver Street, Sewickley, Pennsylvania 15143.

     

    (c) Citizenship:

     

    NLLC is a limited liability company organized under the laws of the State of Florida. Mr. Newlin is a citizen of the United States.

     

    (d) Title and Class of Securities: Common Stock, $0.001 par value per share

     

    (e) CUSIP Number: 142922103

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

           
      (a) ¨  Broker or dealer registered under Section 15 of the Act;
           
      (b) ¨  Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ¨  An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨  An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ¨  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ¨  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
      (j) ¨  A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨  Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     

     

     

    CUSIP No. 142922103       Page 5 of 8 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount Beneficially Owned:

     

    NLLC – 1,249,062

    Mr. Newlin – 1,249,062

     

    (b) Percent of Class:

     

    NLLC – 5.4%*

    Mr. Newlin – 5.4%*

     

    (c) Number of shares as to which NLLC has:

     

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 1,249,062

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 1,249,062

     

    Number of shares as to which Mr. Newlin has:

     

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 1,249,062

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 1,249,062

     

    *Shares reported herein are held by NLLC. Mr. Newlin serves as the Chairman of NLLC.

     

    By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934 (the “Act”), Mr. Newlin may be deemed to beneficially own the shares directly owned by NLLC.

     

    The percentages herein are calculated based upon 23,081,642 shares reported as outstanding as of November 14, 2023, in the Quarterly Report on Form 10-Q filed with the SEC on November 15, 2023, by Issuer.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the subsidiary which acquired the security being reported on by the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

     

     

     

    CUSIP No. 142922103       Page 6 of 8 Pages

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

     

     

     

     

    CUSIP No. 142922103       Page 7 of 8 Pages

     

    EXHIBIT INDEX

     

    Ex.   Page No.
    99.1 Joint Filing Agreement 1
    99.2 Power of Attorney 1

     

     

     

     

    CUSIP No. 142922103       Page 8 of 8 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 6, 2024

     

      NEWLIN INVESTMENT COMPANY 1, LLC
       
      By: /s/ William R. Newlin
      William R. Newlin
      As attorney-in-fact for Newlin Investment Company 1, LLC
       
      WILLIAM R. NEWLIN
       
      /s/ William R. Newlin

     

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, Provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Get the next $ALPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cassaday Bryan J. bought $1,540 worth of shares (440 units at $3.50), increasing direct ownership by 29% to 1,940 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/19/23 5:00:05 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Spenlehauer Gilles bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:13:12 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Frisch Scott M. bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:12:55 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Shukla Rajiv was granted 14,347 shares and acquired 0 shares, increasing direct ownership by 42% to 48,526 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    1/4/24 9:17:09 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Cassaday Bryan J. bought $1,540 worth of shares (440 units at $3.50), increasing direct ownership by 29% to 1,940 units (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/19/23 5:00:05 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Spenlehauer Gilles bought $3,456 worth of shares (904 units at $3.82) (SEC Form 4)

    4 - Carmell Corp (0001842939) (Issuer)

    12/18/23 5:13:12 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Healthcare Acquisition Corp. III Announces Successful Closing of Business Combination with Carmell Therapeutics Corporation

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the successful completion of its business combination (the "Business Combination") with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). The resulting combined company, Carmell Therapeutics Corporation, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Capital Market® under the ticker symbols "CTCX" and "CTCXW," respectively, on July 17, 2023.

    7/14/23 3:12:00 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III Announces Non-Binding Letter of Intent to Acquire a Commercial Stage Regenerative Medicine Company Conditioned Upon Closing of Carmell Business Combination

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the "LOI") to acquire a commercial stage regenerative medicine company (the "Target") conditioned upon the closing of ALPA's initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). ALPA has set a Stockholders Meeting (the "Meeting") to consider the previously announced business combination with Carmell for J

    6/27/23 7:00:00 AM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications

    Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation ("Carmell™"), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications. Upon closing of the transaction, ALPA will be renamed Carmell Therapeutics Corporation (the "Combined Company"). Mr. Shukla will serve as Chairman and Mr. Randy Hubbell will serve as Chief Executive Officer of the Combined Company. The Combined Company's common stock is expected to be listed on the Na

    1/4/23 10:11:00 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    SEC Filings

    View All

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:27:40 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:14:47 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Carmell Corp (0001842939) (Filer)

    1/16/24 7:07:47 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    $ALPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    2/14/24 4:13:13 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    2/14/24 3:42:33 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III

    SC 13G - Carmell Corp (0001842939) (Subject)

    2/14/24 12:54:27 PM ET
    $ALPA
    Medical/Dental Instruments
    Health Care